Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
493 Cards in this Set
- Front
- Back
screening tests for cystic fibrosis
|
1. IRT
2. DNA analysis 3. Sweat Test (>60) |
|
Pathophysiology of Cystic Fibrosis
|
1. Increased mucous viscosity w/ obstruction of lungs, GI tract, Liver, gall bladder, reproductive tract.
2. Respiratory tract colonization/ infection with unique organism 3. increased sodium chloride in serous secretions |
|
Common Treatmnet of Cystic Fibrosis
|
1. pulmozyme (DNAse)
2. Tobramycin (TOBI) 3. Azithromycin 4. Inhaled hypertonic saline 5. Inhaled Aztreonam (Caystor) [airway clearance] [diet/ high protein] [pancreatic enzyme supplements] |
|
Primary Cause of Down's Syndrome
|
Non-disjunction in Meiosis I in the maternal line resulting in three copies of chromosome 21. [95% of cases]
|
|
Diagnosis of Down's Syndrome
|
Karyotyping; FISH may be used to get a quick preliminary diagnosis, but it should always be followed by a karyotype to verify.
|
|
Prenatal Screening for Down's Syndrome
|
Serum Measurements [indicative, but not diagnostic]
amniocentesis for karyotyping |
|
Pathology of Down's Syndrome
|
1. Growth delay
2. Cardiac a. atrioventricular septal defects[AVSD] b. ventricular septal defect [vsd] c. atrial septal defect [asd] 3. gastrointestinal: duodenal atresia or stenosis, imperforate anus 4. myopia and cataracts; protruding tongue; hearing loss [leukemia 400X more likely] |
|
Most Common Mode of Lysosomal Storage Disease
|
AR: inability to break down glycoproteins
|
|
Biochemical Abnormalities Leading to Lysosomal Storage Disease
|
1. enzyme deficiency
2. inability to activate lysosomal enzymes 3. abnormality of lysosomal membrane proteins 4. inability to transport enzymes to lysosomes 5. abnormal lysosome structure |
|
Clinical Features of Lysososomal Storage Disease
|
Abnormal facial features, thickened oral and airway tissues, skeletal abnormalities, enlarged organs, CNS [neurodegeneration, cerebral atrophy, leukodystrophy, mental retardation, seizures]
|
|
Therapy of Lysosomal Storage Disease
|
substrate reduction and enzyme replacement therapy [sometimes chaperone therapy, bone marrow transplantation, liver transplantation, gene therapy]
|
|
Treatments for Sickle Cell
|
1. penecillin until the age of 5
2. hydroxyurea- stimulates the synthesis of HgF to replace HgB [for crises: heat and hydration NSAID and Narcotic] |
|
Osteogenesis Imperfecta
|
"Brittle Bone Disease"
impairs triple helix formation of collagen especially bad if point mutation occurs near the C-terminus |
|
What is necessary to form crosslinks between tropocollagens?
|
Lysyl oxidase and copper
|
|
What is needed to hydroxylate the proline in collagen formation?
|
prolyl hydroxylase, iron, and vitamin C [ascorbate]
|
|
Ehlers-Danlos Syndrome
|
characterized by stretchy skin; loose joints; poor wound healing; failure of vessel/ organ structure
no cross-linking or no removal of the n-peptide end of tropocollagen [not converted to insoluble form] |
|
Elastin
|
rubber protein [3d network of crosslinks
made of small nonpolar AA; abundant in proline and lysine 2 chains with 4 crosslinks formed by lysyl oxidase and copper |
|
Elastase
|
1. degrades elastin for remdeling
2. inhibited by alpha-antitrypsin |
|
Emphysema
|
mutation in alpha- antitrypsin; elastase degrades elastin in the lungs at too rapid a rate
|
|
Keratin
|
1. repeats of 7 AA
2. has polar and non-polar surfaces micro to macroscale; alpha helix-protofibril-microfibril-macrofibril of har 3. cystine cross links; insoluble and not stretchy |
|
What happens if trypsin is activated prematurely?
|
Accute pancreatitis; early activation [cleaving of zymogen in the pancreas, rather than in the intestines] will lead to digestion, by trypsin, of the pancreas
|
|
Types of Post-translational Modification
|
1. folding [aided by chaperones]
2. proteolytic cleavage [cleavage into segments or removal of ends] 3. chemical modification [phosphorylatio, glycosylation, ubiquitination] |
|
Phosphorylation Is very common on which Amino Acid?
|
Serine; Threonine; Tyrosine
|
|
Glycoprotein
|
n-linked are constructed and then added in the RER
o-linked are built directly on in the Golgi Apparatus |
|
How does the cell recognize which glycoproteins are destined for the lysosome?
|
the protein is labeled with the mannose-6-phosphate sugar
|
|
Proteosomes degrade what?
|
ubiquitinated intracellular proteins
|
|
Types of Enzymes?
|
1. oxidoreductases
2. transferases 3. hydrolases 4. lyases 5. isomerases 6. ligases |
|
Enzymes may use which cofactors?
|
1. Metal ions [2/3 of enzymes need metal]
2. coenzyme 3. prosthetic group |
|
Diagnostic lab test for pancreatitis?
|
blood work to look for elevated levels of pancreatic lipase and anylase
|
|
Types of Inhibitors
|
1. Irreversible; covalent; inactivates the enzyme [ie. Aspirin on cyclooxygenases]
2. reversible a. competitive; higher Km b. noncompetiteve; lower Vmax. |
|
Control of Enzyme Activity [FAST]
|
[S] or allosteric controls
|
|
Control of Enzyme activity [ intermediate]
|
1. covalent modification
2. modular proteins 3. zymogen activation |
|
Control of Enzyme Activity [SLOW]
|
transcription or translation
|
|
tPA
|
activates plasmin to cut fibrin
removes the clot given medicinally to limit the size of an infarction |
|
Aspirin
|
irreversible inhibitor of cyclooxygenases; inhibits clotting [ regenerated by healthy endothelial cells, not platelets]
|
|
EACA
|
E-aminocaproic acid; competetive plasmin inhibitor
slows clot removal [often used in surgery, but keep heparin rady] |
|
What is special about Selenocyseine
|
a special tRNA for 'stop' codon
|
|
Basic Structure of the Nuclear Hormon Receptors
|
a DNA binding domain [DBD] and a ligand binding domain {LDB}
DNA binding proteins[ zinc fingers] conformational change upon ligand binding. |
|
Types of dimerization
|
homo dimerization [same type of protein]
heterodimerization [different type of protein] |
|
G-Protein Coupled Receptors [GPCR]
|
seven transmembrane domain receptors;
largest family of cell surface receptors; 30% of drugs target GPCR; |
|
cAMP
|
cyclic AMP;
created by adenyl cyclase; activates PKA, CREB, BCL-2; deactivated by phospodiesterase |
|
PIP2
|
activated by GPCR;
activates IP3 Ca channel; activates protein kinase C which binds to DAG |
|
Calmodulin
|
helps Ca do its job
|
|
RTK activation
|
receptor tyrosine Kinase; dimerized and phosphorylated
|
|
RTK activates which important protein?
|
RAS
|
|
PTEN
|
tumor suppressor on the PIP2 pathway
|
|
Howis PIP3 made and what does it do?
|
PIP2 is converted by p85, p110, and PI3K which activates PTEN
|
|
JAK/STAT
|
Jaks activate stats which dimerize and transcribe
|
|
Functions of TGF-B
|
1. inhibit epithelial growth
2. inhibit immune functions 3. promotion of connective tissue growth |
|
TGF-B pathway
|
activates SMAD2; which binds to SMAD 4; leads to transcription
|
|
What will a mutation in the TGF-B receptor lead to?
|
colon and gastic cancer
|
|
What will mutations in the SMAD4 protein lead to?
|
pancreatic and colorectal tumors
|
|
What will mutations in the SMAD2 protein lead to?
|
colon cancer
|
|
Why is TGF-B bad?
|
can exacerbate tumor growth by suppression of immune surveilance and by fostering tuor invasion and metastisis
|
|
WNT pathway
|
ligand binds to frizzeled and WNT; bind to axin; allowing B catenin to transcribe
|
|
Functions of WNT
|
cell fate; remodeling, polarity and morphology, adhesion, growth;
especially important in embryogenesis |
|
carcinogenesis
|
the process by which cells acquire attributes that confer a malignant phenotype
|
|
What does telomerase do in respect to cancer?
|
helps the cell to avoid senescence or natural cell aging; leading to avoidance of apoptosis
|
|
The loss of cadherins is a major factor in what hallmark of cancer?
|
metastasis; cells are no longer bound together and may move freely
|
|
What do cancer cells do to harness more energy?
|
Aerobic glycolysis;
inefficient, but may get energy slightly faster |
|
How do cancer cells escape immunodetection?
|
turnoff antigen expression; secrete antiproliferative factors;
TGF-B |
|
Microsatellite instability reflects?
|
decreased DNA repair; NER
|
|
miRNA
|
microRNA
noncoding; downregulate gene expression in development and oncogenesis |
|
Hematoma
|
coagulated blood tissue
|
|
choristoma
|
ectopic or heterotopic normal tissues [normal in an abnormal location]
|
|
granuloma
|
chronic inflammation
|
|
H & E staining
|
hematoxylin + basophilic; RNA, DNA, cartilage
Eosin - acidophilic; proteins |
|
hamartoma
|
overgrowth
|
|
neoplasms
|
1. benign tumors
2. malignancies; metastisize 3. hamartomas |
|
Carcinoma
|
cancer of the epithelium; non-glandular
|
|
adenocarcinoma
|
cancer of the wpithelium; glandular
|
|
sarcoma
|
cancer of connective tissue
|
|
leukemia
|
cancer blood
|
|
lymphona
|
cancer of lymph tissue
|
|
high-grade cancer
|
does not look like tissue of origin [anaplatic]
|
|
oncogene
|
KRAS, HER2
normal gene that, when mutated to active form, contributes toward the neoplastic phenotype |
|
tumor suppressor gene
|
pRB, TP53
when tumor suppressor gene is absent, cellular events that either express the malignant phenotype proceed at a higher rate |
|
Hallmarks of Cancer
|
1. resist cell death [apoptosis]
2. sustain proliferatice signaling 3. evade growth suppressors 4. induce angiogenesis 5. enable replicative immortality 6. activate invasion and metastisis |
|
function of BCL-2
|
limits the signal for apoptosis
|
|
HER2
|
RTK; if mutated, patient may be responsive to herceptin [trastuzumab]
|
|
Function of RB
|
inhibit the growth signal;
antigrowth signal>cell surface receptor>cyclin D> RB> E2F Master brake for the G1/S phase checkpoint |
|
Prostate Cancer preferentially metastisizes where?
|
bone marrow>liver>lungs>brain
|
|
Pancreatic cancer preferentially metastisizes where?
|
Liver> lungs
|
|
Breast Cancer preferentially metastisizes where?
|
bone marrow>lungs>liver>brain
|
|
Colon Cancer preferentially metastisizes where>
|
liver> lungs> bone marrow
|
|
Key Guardian of the genome?
|
p53 a tumor suppressor
|
|
Chronis Myelogenous Leukemia is characterized by?
|
anemia and fatigue
philadelphia chromosome BCR-ABL |
|
What tumor suppressor works on early adenomas?
|
APC
|
|
What tumor suppressor works on intermediate adenomas?
|
KRAS
|
|
What tumor suppressor works on late adenomas?
|
DCC
|
|
What tumor suppressor works on carcinomas?
|
p53
|
|
Familial Adenomatous Polyposis
|
Carpeting of Polyps in the colon [AD]
usually caused by a loss of APC, a tumor suppressor |
|
Genes expressed from the inactive X chromosome
|
XIST specifically[ 16 total form the pseudoautosomal region]
|
|
3 major types of fibrous proteins
|
1. collagen
2. elastin 3. keratin |
|
what is the most abundant protein?
|
collagen
|
|
Structure of collagen?
|
GPx; glycine every 3 AA
triple helix; proline is posttranslationaly modified to hydroxyproline induces mor H-bonding between fibers in the helix |
|
What is hydroxylated in collagen synthesis?
|
proline and lysine
|
|
What is glycosylated in collagen synthesis?
|
hydroxylysine
|
|
Which way does the triple helix structure of collagen zip up?
|
c to n-terminus
|
|
What happens after the procollagen is secreted from the cell?
|
1. n and C ends are cleaved
2. tropocollagens stagger [1/4] together 3. cross-linking of lysines by lysyl oxidase |
|
Scurvy
|
skin lesions; poor wound healing; fragile bones; and bloody gums after brushing
caused by a vitamin C deficiency; lysyl oxidase does not work |
|
Kinases
|
phosphorylate proteins
|
|
phosphatases
|
enzymes that remove phosphates
|
|
What proteins usually undergoes glycosylation?
|
on extracellular and embrane bound proteins
|
|
How does the cell know where the protein go?
|
the proteins contain a sorting signal recognized by the destination site; the nucleus uses importin alpha and beta
|
|
erythrocyte
|
RBC [red blood cell] contains hemoglobin
|
|
Location of Myoglobin
|
Muscle
|
|
Locaton of Hemoglobin
|
blood
|
|
heme
|
complex of iron and porphyrin
[sheilded from water by Hb and Mb- If water does get in <MHb> methemoglobin] |
|
Hb basic structure
|
2 alpha and 2 beta subunits each holding a hem in place with his
|
|
Does Mb or Hb have a higher affinity for O2
|
Mb
|
|
how can you tell, graphically, what has a higher affinity?
|
lower Km
|
|
Forms of Hb? [allosterism]
|
raelaxed and taut
|
|
What is the effect of lower pH on Hb?
|
decrease of affinity for O2
|
|
What effect does CO2 have on hemoglobin?
|
decreases its affinity for O2
|
|
What does BPG do to Hb?
|
tightens the bonding; decreases the affinity for O2
necessary to get mor O2 to the body in high altitudes |
|
Does HgF interact with BPG?
|
very little
|
|
Why does fetal hemoglobin take O2 from the maternal blood?
|
The HgF does not bind well with bpg, increasing its relative affinity for O2 compared to the maternal blood. So as the O2 is released from the maternal blood, the fetal blood will act like myoglobin and pick it up.
|
|
Effect of CO on Hb?
|
binds 200X more tightly than O2, severely decreased affinity for O2;
treat with excess O2 |
|
Effect of CN on Hb?
|
nothing; Bad for mitochondria
|
|
how do you treat CN in body?
|
amyl nitrate
|
|
What does amyl nitrate do in blood?
|
converts Hb to methemoglobin which bind to CN; done to save the mitochondria. Should be careful in dosing, only give enough o convert some of the hemoglobin. Too much would be fatal.
|
|
Hb Kansas
|
ultrarelaxed hemoglobin form: cells will compensate for decreased O2 affinity by cramming 20% more Hb into the RBC
|
|
Hb S, Hb D, Hb E, Hb C
|
forms of sickle cell: decreased solubility and sickling occurs when the cell reaches the deoxy or tight form.
|
|
Thalassemias
|
truncation of Hb polypeptide; may have limited function
can sometimes activate HbF to compensate |
|
How do you turn on HbF?
|
hydroxyurea
|
|
What does cyanate do in respect to Sickle Cell?
|
increases O2 affinity; no deoxy form
|
|
Methods of Enzyme Catalysis
|
concentrating, orienting, straining, dividing
|
|
How do enzymes catalyze
|
decreasing the activation energy by stabilizing the transitional state
|
|
Enzyme RXN pathway
|
E + S= ES= E+P
|
|
Assumption of Michaelis-Menten Model of Enzyme Catalysis:
|
[S] or allosteric controls
|
|
Why is an allosteric enzymes plot sigmoidal?
|
it controls itself based on the [s] and[p]
|
|
von Willebrand factor
|
1. exposed in the collagen of subendothelial cells
2. binds to receptors on platelets 3. aids in the formation of soft blug |
|
Charge of activated platelets?
|
negative: PS flips to create the - charge on the surface
|
|
Which pathway do hemopheliacs use for the coagulation cascade?
|
extrinsic; they are usually fine except in muscles and joints where tissue factor is not present.
|
|
Coumarin
|
a competitive inhibitor for gamma-carboxyglutaminase/ vitaminK
|
|
Heparin
|
widely used anti coagulant helpd thrombin and antithrombin III get together
|
|
Removal or change of single amino acids can do what in proteins?
|
1. perturb the structure and conformation
2. remove a critical residue 3. alter the interaction of one protein with another 4. destabilize a protein resulting in a shorter biological half-life |
|
Basic structure of an amino acid
|
alpha carbon flanked by an amino group and a carboxyl group; with an R constituent
|
|
What is special about glycine?
|
has an H side chain; small and packs tightly
|
|
What is special about cysteines?
|
can form a disulfide crosslink
|
|
What is special about proline?
|
has a cyclic side chain that is incompatible with the alpha helix that creates a kink or quick turn
|
|
Levels of Protein Structure
|
1. primary; peptide
2. secondary; alpha helix, beta sheets 3. tertiary; 3d structure of a single protein 4. Quarternary; multiple protein structure |
|
Types of post-translational modifications
|
1. disulfide crosslinking
2. phosphorylation 3. glycosylation 4. proteolytic processing 5. accessory /co-factor |
|
Prion
|
diseased protein that has undergone a conformation change; when a prion comes in contact with a non-diseased protein it will induce the same conformational change in the protein.
|
|
What is a peptide bond?
|
the bond between amino acids in a polypeptide chain; water is given off
|
|
Intracrine Signaling
|
signal is produced within a cell and targets cell
|
|
Autocrine signaling
|
signal is excreted and targets the same cell
|
|
Juxtacrine signaling
|
signal is sent via direct connection to target cell
|
|
Paracrine signaling
|
signal over a short distance
|
|
Endocrine signaling
|
signal over a long distance (estradiol)
|
|
What kind of ligand can enter the cell?
|
hydrophobic
|
|
Types of nuclear hormone receptors
|
HSP; heat shock protein
constitutively nuclear |
|
Agonist
|
bind and activate
|
|
Antagonist
|
bind and repress
|
|
Effect of Cholera Toxin on cAMP
|
prolonged elevation
|
|
Effect of Pertussis Toxin on cAMP
|
increased cAMP levels
|
|
Notch Pathway
|
disposable; only one signal can be used
|
|
NF-kB Pathway
|
activates IkB kinase; usually involved in inflammatory or autoimmune response
|
|
HNPCC
|
Lynch Syndrome; hereditary non-polyposis colon cancer
|
|
What mutation predicts decreased responsiveness to monclonal Ab (herceptin) therapy agains EGFR?
|
KRAS mutations
|
|
BRAF
|
associated with melanomas mutations in the RAS pathway; may respond to BRAF kinase inhibitor
|
|
Which neoplasms are always malignant
|
melanoma, lymphoma, glioma, teratoma
|
|
fibro-
|
connective tissue
|
|
leiomyo-
|
smooth muscle
|
|
rhabdomyo
|
striated or skeletal muscle
|
|
lipo-
|
fat
|
|
chondro-
|
cartilage
|
|
osteo-
|
bone
|
|
lymphangio-
|
lymph fluid
|
|
hemangio-
|
blood
|
|
scirrhous
|
hard
|
|
zonula adherens
|
cadherin adhesion belt at apical end
|
|
zonula occludens
|
tight junctions at apical end
|
|
Desmosome
|
junction in cells anchored with keratin; cadherin in between cells
|
|
gap junction
|
pores made of connexons; known as connexins; allow rapid flow of small particles between adjacent cells
|
|
relative sizes of microfilaments
|
actin< keratin< microtubules
|
|
Cilia
|
doublets of micrtubules at the plasma membrane that aid in movement
|
|
centriole
|
starting point of microtubules; aid in cell division
|
|
microvilli
|
have an actin skeleton about 1/10 the size of cilia
|
|
gated transport
|
used by the nucleus
|
|
peroxisome
|
carries out oxidation reactions
|
|
Lysosomes
|
pH of 5 break down waste
|
|
mannose-6-phosphate
|
ligand for lysosomal pathway
|
|
1st cellular pathway
|
at the end of G1, starts the synthesis of DNA, asks if the environment is favorable?
|
|
G2/M checkpoint
|
Is all Dna replicated? Is environment favorable?
|
|
Metaphase to Anaphase Checkpoint
|
Are all chromosomes attached to the spindle?
|
|
Cyclin dependent Kinase
|
inhibited by p21 , moves cell through checkpoints
|
|
Do cancer cells have cilia?
|
No
|
|
Mitogen
|
Cell growth ligand
|
|
p53
|
will transcribe a protein that inhibits cdk; which inhibits mitosis and cell division
|
|
medullary
|
soft
|
|
colloid
|
muconous or secreting mucous
|
|
cystic
|
having a void space lined with epithelial cells
|
|
papillary
|
nipple-like projection
|
|
villous
|
having a frond-like pattern
|
|
cribriform
|
inside a duct/ having a cookie cutter appearance
|
|
hemidesmosomes
|
on the basal surface incvolve integrins
|
|
mRNA has distinctive features
|
1. 5' cap
2. polyA tail 3. Uracil instead of T |
|
Central Dogma of Genetics
|
Trascription>Translation>Modification
|
|
Stop Codons
|
1. UAG
2. UGA 3. UAA |
|
Start Codon
|
AUG
|
|
Alternate Splicing
|
The splicing of different exons in a gene to code for different proteins
|
|
What does imprinted mean?
|
inactivated or silenced
|
|
Mitochondria code for how many peptides and where are they utilized?
|
13 peptides used exclusively in the mitochondria
|
|
Do mitochondria have introns in their DNA?
|
no
|
|
What are analogues of purine/pyramidines currenlty being used for?
|
cancer treatments or antiretroviral; they are introduced into DNA and replace normal nucleotides; this causes a degredation of the DNA
|
|
DNA Cloning?
|
used for copying a small fragment of DNA; used to create DNA libraries.
|
|
PCR
|
Polymerase Chain Reaction; a fst, cheap, easy method to amplify DNA of interest using TAQ; completely in vitro
|
|
RT-PCR
|
reverse-transcriptase PCR; can compare with normal PCR to detect splice site mutations
|
|
Southern Blot
|
DNA gel electrophoresis
|
|
Northern Blot
|
RNA gel electrophoresis
|
|
Western Blot
|
Protein Gel electrophoresis
|
|
SNP
|
single nucleotide polymorphism
|
|
Sanger's sequencing
|
substitution of dideoxysugar base with a standard nucleoside; severs chain at that point; measure and sequence[ run 4 times for each type of nucleotide]
|
|
Missense
|
SNP leading to a different amino acid
|
|
Nonsense
|
SNP leading to a premature stop codon
|
|
splice site mutation
|
SNP leading to the addition or removal of a splice site
|
|
Types of long mutation
|
1. deletion
2. duplication 3. insertion 4. expansion |
|
Frameshift Mutation
|
a mutation causing a change in the 'reading' frame
|
|
Anticipation
|
growth of a mutation [in expansion related mutation] through geneology
|
|
What test is good for large changes in DNA?
|
Southern Blot; also PCR
|
|
Hot' spots for Mutations on DNA
|
CpG islands; usually by spontaneus deamination of a methylated cytosine
|
|
NER
|
nucleotide excision repair; removes thymine dimers
|
|
What causes xeroderma pigmentosum?
|
lack of NER; only treatment is to avoid UV light
|
|
BER
|
base excision repair; mutations associated with colorectal polyposis
|
|
How is a mitochondrial disorder passed on?
|
by the mother to all of her progeny. Variable expression due to heteroplasmy.
|
|
AD
|
Autosomal Dominant; 50 % chance of passing it on for each child of an affected parent; variable expression due to non-penetrance, and imprinting
|
|
AR
|
Autosomal Recessive; 25% chance for each child and 50 % chance of being a carrier; cariable expression due to consanguinity, population genetics
|
|
XLR
|
X linked recessive; 50 % chance for sons of female carriers; variable expression due to x inactivation
|
|
Multifactorial Disease
|
Mendelian genetics vs. environmental factors
|
|
Hardy-weinberg equation
|
p^2+2pq+q^2=1; q= homozygous recessive
|
|
RFLP
|
restriction fragment length polymorphism; DNA is cut and run to determine lengths and approximate sequence using specific cutting tools
|
|
Linkage
|
mapping of crossing-over events of chromosomes in the tetrad formation; can use markers to determine how frequently thay are recombinant; if they are infrequently seperated, they are said to be linked
|
|
1 cM
|
1 centiMorgan; the genetic distance between two loci where there is only 1% chance of seperation by recombination; approximately 1 Mb
|
|
LOD score
|
Odds of Linkage; >3 evidence of linkage, <-2 evidence against linkage
|
|
homozygosity mapping
|
only useful in AR; determining location by geneology and mapping
|
|
Exome sequencing
|
the use of SNPs to attempt to find missense/ nonsense mutations in distinctive cases
|
|
Locus heterogeneity
|
mutations on different genes causing the same disease
|
|
Allelic heterogeneity
|
mutations on the same chromosome causing the different diseases
|
|
G-Banding
|
Giemse Stain; the standard for staining chromosomes during metaphase or prometaphase in order to identify them.
|
|
euploidy
|
chromosomes are a multiple of 23
|
|
aneuploidy
|
chromosomes are not a multiple of 23
|
|
A chromosomal microdeletion is best diagnosed by?
|
Fish Analysis; flourescent in situ hybridization
|
|
Prader Willi Syndrome needs which working copy?
|
Paternal UBE3A
|
|
Angelman Syndrome needs which working copy?
|
Maternal UBE3A
|
|
What are the possible uses of FISH?
|
1. diagnose chromosomal microdeletion
2. diagnose aneuploidies 3. indentify chromosome translocations [robertsonian also] |
|
CBAVD
|
congenital bilateral absence of Vas Deferens
|
|
deltaF508
|
most common mutation in cystic fibrosis
|
|
Sweat test for Cystic Fibrosis
|
>60 mmol/L sweat Cl- in two occurrences; used to diagnose 90% of CF
|
|
Cystic Fibrosis
|
1. AR
2. chronic respiratory tract infection 3. pancreatic insufficenccy 4. elevated sweat electrolytes 5. CBAVD- most males infertile [prevalent in caucasians of european descent] |
|
Huntington's Disease
|
1. AD
2. chorea movements 3. progressive dementia 4. CAG triplet expansion[34-120 repeats] leading to a gain of function 5. anticipation present [prevalent in europeans and esp. venezualans. |
|
How does Huntington's disease expand?
|
through the paternal line
|
|
What is ptosis?
|
Bedroom eyes; can be associated with Oculopharyngeal Muscular Dystrophy
|
|
Duchenne's Muscular Dystrophy
|
1. XLR
2. hypotonia 3. progressive muscle weakness and wasting 4. gower's maneuver 5. mostly affects males 6. out-of-frame mutation |
|
How do you test for Duchenne's MD?
|
1. PCR
2. Gower's maneuver 3. southern blot 4. northern blot 5. serum creatine kinase [ elevated 50-100 fold] 6. last resort- muscle biopsy |
|
Cause of DMD?
|
Large deletion on the dystrophin gene causing a frameshift nonsense mutation
|
|
What is Becker's Muscular Dystrophy?
|
similar to Duchenne's, although the deletion resulted in an infram shift. Some dystrophin is still produced. Symptoms are milder
|
|
Exon 'hot' spots for mutations on the Dystrophin Gene
|
1-20 and 45-53
|
|
What is the ratio for DMD de novo cases?
|
0.33333333333333
|
|
How do you confirm the clinical diagnosis of DMD?
|
1. uimmunohistochemical staining
2. western blot 3. PCR/ southern blot |
|
What is Gonadal Mosaicism?
|
Mutation in the germline cells; mother can have this mutation and not be a 'carrier' for the mutation.
|
|
Gentamicin may be used for what?
|
treatment of Duchenne's MD; forces a read-through of the nonsense mutation;
possibly restore reading frame and decrease severity of symptoms |
|
Fragile X Syndrome
|
1. XLD
2. CGG expansion through maternal line [>230 repeats][hypermethylated] 3. FMR1 gene 4. prepubertal males; language delays; hyperactivity |
|
FXTAS
|
prefragile X syndrome; expanded maternally
|
|
Sensitivity
|
frequency of + test when the disease is present
|
|
specificity
|
frequency of - test when the disease is absent
|
|
Prenatal Screening Programs
|
1. maternal serum alpha fetoprotein [MSAFP][identify fetus w/open neural tube defect
2. triple test [identify fetus with down's] |
|
Types of prenatal screens [procedure]
|
1. amniocentesis [detects neural tube defects][ late in pregnancy]
2. chorion villus sampling [early in pregnancy] |
|
Antisense oligonucleotides
|
are being used to induce exon skipping to restore open reading frame.
|
|
Number of genes in the human genome
|
approx. 25000
|
|
number of genes in mitochondrial DNA
|
37
|
|
Percentage of the human genome actually coding for proteins
|
1-2%
|
|
Pyramidines
|
CUT
|
|
Purines
|
AG
|
|
Acrocentric
|
centromere is located grossly to one side of the chromosomes [13,14,15,21,22]
|
|
Metacentric
|
centromere is located in the middle of the chormosome
|
|
submetacentric
|
centromere is located away from the middle and the ends of the chromosomes
|
|
Reciprocal translocation
|
parts of chromosomes are 'swapped' equally
|
|
robertsonian translocation
|
part of one chromosome is moved ot another
|
|
telomere
|
The end of the chromosomes; seems to protect the functional portion of DNA; preserved by telomerase
|
|
Tandem Repeats
|
short repeats of codonc or nucleotides used in paternity testing;
|
|
euchromatin
|
active
|
|
heterochromatin
|
inactive
1. always off-constitutive 2. facultative- switched on/off |
|
methylation
|
process to deactivate segments of DNA; occurs at CpG islands
|
|
What is needed to synthesize DNA?
|
1. primers
2. DNA template 3. DNA polymerase 4. dNTPs 5.Mg+ |
|
Charge and handedness of DNA molecule
|
[-] charge and right-handed in beta-form
|
|
Types of DNA transfer
|
1. transformation
2. conjungation 3. transduction |
|
What is a zygote?
|
fertilized egg
|
|
Ribosome
|
responsible for mRNA translation for production of amino acids
|
|
Okizaki Fragments
|
additions by short fragments of DNA to the 5' end of the lagging strand during semi0-conservative replication
|
|
Where does replication begin?
|
in an A-T rich region followed by Dna A boxes
|
|
Centromere
|
compacted 'middle' of the chromosome
|
|
nucleolus
|
where ribosomal subunits are assembled
|
|
chromatin
|
relaxed and jumbled chromosomes
|
|
what is a chiasma?
|
a tetrad formation of chromosomes in meiosis
|
|
Steps to mitosis?
|
1. Prophase
2. Metaphase 3. Anaphase 4. telophase 5. interphase |
|
Steps to Meiosis?
|
1. Prophase I
2. Metaphase I 3. anaphase I 4. telophase I 5. Prophase II 6. Metaphase II 7. Anaphase II 8. Telophase II |
|
What is the gestational age based on?
|
age based upon the time from the last normal menstrual period
normal parturition=40 wks |
|
What is fertilization age based on?
|
age based on the actual time of fertilization
normal parturition is 38 weeks |
|
What weeks in early human development are considered to be the embryonic stage?
|
weeks 1-8
characterized by the organogenic period also the time most susceptible to teratogens |
|
What are the characteristics of the Fetal period in early human development?
|
weeks 9-38
further development of organs and systems extensive growth |
|
At which point in development does it become possible to survive premature birth and why?
|
at 24 weeks, the lungs have developed sufficiently; however extensive care will be necessary
|
|
What happens to the lungs after birth?
|
Because only 10-15% of alveoli necessary for survival are present at birth, further development and growth will continue after birth.
|
|
What happens in the cardiovascular system after birth?
|
the closure of fetal chunts and vessels
|
|
What happens to the nervous system postnatally?
|
continued neuronal development
|
|
What are the five key processes that must occur for the development of a zygote into a neonate?
|
1. proliferation
2. growth 3. differentiation 4. pattern formation 5. morphogensis |
|
How is differentiation defined?
|
the process by which cells or tissues become different from one another.
Also, the progressive acquisition of structural and biochemical specializations leading to unique or highly developed cellular functions |
|
Define totipotent.
|
able to differentiate into all cell types
|
|
Define Pluripotent.
|
able to differentiate into many cell types
|
|
Define Multipotent.
|
able to differentiate into a restricted group of cells.
|
|
Define Unipotent.
|
determined as to differentiated cell form
|
|
Does differential gene activity lead to irreversible turning off of genes?
|
No
|
|
What is the SHH factor important for?
|
sonic hedgehog
inducing positional growth formations |
|
What is syndactyly?
|
a malformation due to altered morphogenesis in which two fingers are fused together due to the lack of apoptosis in the cells between the fingers in development
|
|
Briefly describe what happens during the first week of development.
|
1. oocyte released and fertilized
2. rampant cleavage; development of morula 3. compaction and fusion of outer blastomeres; formation of blastocyst 4. hatching of blastocyst from the zona pellucida 5. implantation with syncytiotrophoblasts leading the invasion |
|
In the blastocyst, what is the differentiation potential of the innercell mass?
|
pluripotential
|
|
What are the syncytriotrophoblasts known to secrete?
|
Human chorionic gonadotropin
metalloproteinases to enviade |
|
What is the most imvsive type of carcinoma?
|
choriocarcinoma
|
|
What does hCG do?
|
stops the menstrual cycle
|
|
What is the percentage of spontaneus abortions?
|
thought to be at least 60%
|
|
What is an ectopic pregnancy?
|
pregnancy in which the implantation of the blastocyst has occurred in the fillopian tube, not the uterine body
|
|
What is meant by placental previa pregnancy?
|
the blastocyst implanted in the lower part of the uterine body, possibly on the cervix; leading to the placenta being below the fetus during development and possibly birth
|
|
What is the differentiatio potential of blastomeres?
|
totipotential
|
|
What are 6 possible indications for the use of IVF?
|
In Vitro Fertilization
1. blocked fallopian tubes or pelvic adhesions 2. male factor infertility 3. failed 2-4 cycles of ovarian stimulation with intrauterine insemination 4. unexplained infertility 5. vasectomy or tubal ligation 6. preimplantation genetic diagnosis |
|
What occurs during the second week of development?
|
1. implantation is completed; lies totally within the endometrium
2. formation of primitive uteroplacental circulation 3. formation of bilaminar emryo 4. formation of extraembryonic membranes and cavitied |
|
How does the conceptus hide form the maternal immune system?
|
1. reduces the expression of major histocompatibility complex (MHC) class I antigen
2. produces locally immunosuppressor molecules |
|
What is the lacunar network?
|
network of syncytiotrophoblasts that allow maternal blood to leave the maternal vascular system and enter the embryonic system.
|
|
What is the bilaminar disk?
|
one layer of epiblasts on top of one layer of hypoblasts; above is amniotic cavity, below is blastocyst cavity
|
|
How is the primary yolk sac formed?
|
migration/ expansion of hypoblasts around the blastocyst cavity
|
|
After the thickening of the conceptus wall, what proliferates around the edges?
|
extraembryonic mesoderm; which will form the somatic extraembryonic mesoderm, splanchnic extraembryonic mesoderm and the extraembryonic coelom
|
|
How is the secondary yolk sac formed?
|
the splanchnic extraembryonic mesoderm 'pinches' inward. Excess is degraded and absorbed
|
|
What is the Chorion comprised of form out to in?
|
lacunar network [syncytiotrophoblasts and maternal vascular system], cytotrophoblasts, somatic extraembryonic mesoderm
|
|
what is the allantois, when is it formed, where is ite?
|
part of the secondary yolk sac formed caudaly of the caudal end of the bilaminar disk.
|
|
What is a hydatidiform Molar Pregnancy?
|
over development of extraembryonic structures; paternal only genome
|
|
what drives trophoblast development?
|
paternal genome
|
|
What drives innercell mass development?
|
maternal genome
|
|
3 characcteristics of an epithelial cell?
|
1. polarized
2. apical and basal surface 3. sit on top of the extracellular matrix (ECM) |
|
3 characteristics of mesenchymal cells
|
1. not polarize din ECM
2. surrounded by ECM 3. migrate through the ECM |
|
What layer of the bilaminar disk are all three germ layers formed from?
|
The epiblast.
|
|
What is gastrulation?
|
the process by which the epiblast differentiates into the ectoderm, mesoderm, and endoderm
|
|
What does the ectoderm form?
|
outler layer, skin, nervous system
|
|
What does the mesoderm form?
|
middle layer, muuscle, heart, skeleton
|
|
What does the endoderm form?
|
inner layer, lining of GI tract
|
|
Describe gastrulation.
|
1. occurs through the primitive streak
2. primitive streak is formed by the thickening of the epiblast. 3. ingression of epiblast through primitive groove forms the mesoderm 4. epiblast that ingresses throught the primitive groove replaces hypoblast to form endoderm 5. begins early in the 3rd week of development as is completed by the end of the 4th week. |
|
Describe neuralation.
|
1. process by which the neural tube is formed [brain and spinal cord]
2. neural tube formed and closed by the end of the 4th week of development 3. neural crest cells form as neural tube closes 4. neural crest cell form peripharal ganglia and scwann cells of the nervous system. |
|
Another name for neural crest cells.
|
ectomesenchyme
|
|
Neural tube defects are detected how?
|
ultrasound or measuring alpha-fetoprotein (AFP) in amniotic fluid
|
|
Why is folic acid important?
|
reduces the occurrence of neural tube defect.
|
|
Describe meningocele
|
effect caused by too late degradation of primitive groove; characterized by the meninges protruding into the spine.
|
|
What is meninges?
|
membrane that protects the nervous system.
|
|
Describe meningomyelocele?
|
primitive streak degraded prematurely; causes expose spinal cord out of the spine, but not to the surface; often leads to paralysis beyond that point.
|
|
Describe myelochisis.
|
the premature degradation of the primitive streak resulting in exposure of the spinal cord to the external environment. Often not compatible with life due to infections.
|
|
What is hisrchsprung's disease?
|
aganglionic megacolon; malformation of neural crest cells migration
|
|
What does BMP-4 do?
|
promotes formation of ventral structures
|
|
What does hensen's node do?
|
secretes factors that block BMP-4 [chordin, noggin]
|
|
How does the embryo differentiate between left and right formations?
|
beating of cilia, to the left from the henson node
|
|
Describe what happens during the fourth week of development.
|
1. organization of mesoderm into groups of tissue [notochord, paraxial mesoderm, intermediate mesoderm, lateral plate mesoderm]
2. segmentation of paraxial mesoderm into somites 3. body folding |
|
What will the cephalic somitomeres go on to form?
|
the skull
|
|
What will the occipital somites go on to form?
|
skeleton and muscles
|
|
How many cephalic somitomers are there?
|
7
|
|
How many somite [occipital + trunk] are there?
|
42-44
|
|
In sclerotome formation [axial skeleton] what do SHH and PAX1 do?
|
induce formation of sclerotome and cartilage and bone formation respectively
|
|
In dermamyotome formation, what do WNT, MYF5, BMP4 nad MYOD do?
|
1. induce dermamytome formation
2. epaxial musculature 3. hypaxial musculature |
|
What does Hox do?
|
determines the spatial structure pattern [legs where legs are supposed to go]
|
|
What causes holoprosencephaly?
|
defect in SHH gene possibly from alcohol consumption
|
|
What is produced when a stem cell divides?
|
a stem cell and a cell that must differentiate
|
|
What is transdifferentiation?
|
the conversion of one cell type directly to another
|
|
4 types of stem cell research.
|
1. nuclear transfer
2. iPS cells 3. lineage swithc 4. direct conversion |
|
What doe s the triple screen test for
|
msAFP, betahCG, uE3
|
|
What does the quad screen test
|
all of the triple test, and dimeric inhibin A
|
|
What is pleiotropy?
|
a birth defect demonstrates pleiotropy when a single underlying causative agent results in abnormalities of more than one organ system in different parts of the embryo or in multiple structures that arise at different times during intrauterine life.
|
|
Define syndrome.
|
a syndrome is generally recognized and defined as a well-characterized constellation of major and minor anomalies that occur together in a predictable fashion presumably due to a single underlying etiology which may be monogenic, chromosomal, mitochondrial, or teratogenic in origin.
|
|
What is an association?
|
an association is a group of anomalies that occur more frequently togetherr than would be expected by chance alone, but that do not have a predictable pattern of recognition and or a suspected unified underlying etiology.
|
|
VACTERL
|
an associatio disorder [anal atresia, cardiac anomalies, other]
|
|
Sequence
|
a sequence is a group of related anomalies that generally stem froma single initial major anomaly that alters the development of other surrounding or related tissues or structures
|
|
Field defect
|
the term field defect is often used to describe raltted malformations in a particular region
|
|
Malformation
|
a malformation signifies that fetal growth and development did not procedd normally due ot underlying genetic, epigenetic, or environmentla factors that altered the development of a particular structure
|
|
deformation
|
a deformation is caused by an abnormal external force on the fetus during in utero development that results in abnormal growth or formation of the fetal structure
|
|
Dysplasia
|
dysplasia occurs where the intrinsic cellular architecture of a tissue is not normally maintained thoughout growth and development.
|
|
BMSC
|
bone marrow stem cell
|
|
non seeded technique in bladder
|
creating a biodegradeable scaffolding for the natural cells to use
|
|
Seeding
|
use of stem cells to regenerate
|
|
What is used in recent technology to dice up DNA?
|
miRNA
|
|
What are the number one and number two leading causes of death in the US?
|
1. heart disease
2. cancer |
|
what are the top three most prevalent types of cancer for men?
|
1. prostate cancer
2. lung 3. colon |
|
what are the top most prevalent types of cancer in women?
|
1. breast
2. lung 3. colon |
|
What is the deadliest type of cancer?
|
apparently lung, also the most preventable
|
|
Stages of cancer
|
stage 1: small, localized, generally resectable
stage 2: larger, less resectable, still fairly localized stage 3: lymph node involvement, large, diffuse stage 4: metastasis to one or mor distal sites |
|
At what level does the staging analysis occur?
|
the whole organ level.
|
|
How many grades of cancer are there?
|
4
|
|
What is the first line in cancer therapy?
|
surgery or radiotherapy
|
|
What is the first line in cancer therapy, if surgery and radiotherapy are not safe or effective?
|
chemotherapy
|
|
TPMT
|
thiopurine methyl transferase
metabolizes thiopurine drugs |
|
When giving thiopurine drugs, what is it important to test for?
|
for functioning TPMT
|
|
What are the criteria for combination chemotherapy?
|
1. single therapy alone is effective (for a time)
2. should act by different mechanisms of action 3. should have different mechanisms of resistance |
|
Are chemotherapy drugs given simultaneously in combination therapy?
|
no, the drugs are given individually, but alternating about every 4 weeks
|
|
When is cancer considered cured?
|
when it has been in remission for 10 years
|
|
Toxicities associated with chemotherapy.
|
bone marrow, GI mucosa, oral mucusa, skin [light sensitivity], hair follicle [alopecia], gonads.
|
|
Define Amelioration.
|
to make better
|
|
how to ameliorate myelosuppression in chemotherapy
|
1. Erythrpoietin [EPO][epoetin][epogen]
2. granulocyte colony-stimulating factor [G-CSF][Filgrastim] 3. Granulocyte-macrophage colony-stimulating factor [GM-CSF][Sargramostim/Leukine] |
|
EPO
|
erythropoeitin [epoeitin][epogen]
fx: stimulates production of erythrocytes admin: SC or IV t.5:4-13 h sfx: hypertension, sweating, thrombosis, myocardial infarction, iron deficiency TX:do not use in erythroid based cancer |
|
G-CSF
|
[granulocyte colony-stimulating factor][Filgrastim]
fx: stimulates the production of neutrophiles t.5: ~3 h, but with PEGylation 15-18 h sfx: fever, bone pain TX: do not use in leukemias |
|
GM-CSF
|
[granulocyte-macrophage colony stimulating factor][Sargramostim/Leukine]
fx: stimulates the production of monocytes and granulocytes] t.5: ~3h sfx: fever, rash, bone pain, muscle pain |
|
S-phase specific chemotherapy drugs:
|
antimetabolites
|
|
M-phase specific chemotherapy drug:
|
Taxanes, Vinca alkaloids
|
|
G1-S phase specific chemotherapy:
|
Topoisomerase II inhibitors
|
|
Is it easier to kill dividing cells?
|
yes
|
|
What are cell-cycle nonspecific drugs?
|
1. alkylating agent
2. platinum analogs 3. anthracycline 4. antitumor antibiotics 5. topoisomerase I inhibitors |
|
What do alkylating agents do?
|
[cyclophosphamide][nitrogen mustard]
fx: irreversible changes in DNA[cross-linking og guanines] sfx: mutagenic, teratogenic, carcinogenic USED: lymphoma, leukemia, prostate, lung, breast and ovarian cancer |
|
What do antimetabolites do?
|
[s-phase][methotrexate][folic acid analog]
fx:inhibits dihydrofolate reductase, retards DNA/RNA synthesis also inhibits protein synthesis USED: head, neck, breast and lung carcinoma, sarcoma, testicular and bladder tumors |
|
Mercaptopurine (6-MP)
|
[thiopurine][antimetabolite][s-phase]
acute leukemia, chronic myelogenous leukemia Test for mutations of TPMT! |
|
Azothiopurine
|
[thiopurine][antimetabolite][s-phase]
Test for Mutations of TPMT! |
|
6-Thioguanine (6-TG)
|
[thiopurine][antimetabolite][s-phase]
Test for Mutations of TPMT! |
|
Thiopurines:
|
1. prodrugs requiring activation through the purine salvage pathway
2. act by inducing mutations and by inhibition of de novo purine synthesis 3. toxicity is delayed, since passage through S phase is required 4. also effective as anti-inflammatory and immunosuppressive drugs. |
|
5-FU
|
[antimetabolite][Fluorouracil]
FX: blocks thymidylate synthase converted to FdUMP, FdUTP, FUTP USED: lung, breast, overy, prostate, cervix, bladder, head and neck carcinoma, GI adenocarcinoma |
|
FdUMP
|
1. inhibits thymidylate synthase by blocking access of dUMP
2. causes dNTP imbalance and increased dUTP levels, which lead to DNA damage |
|
FdUTP
|
1. incorporated into DNA
2. induces NER, which is futile in the presence of high FdUTP/dTTP levels, this leads eventually to DNA strand breaks and death |
|
FUTP
|
1. incorporated into RNA
2. inhibits many processes, including processing of pre-mRNA into mature RNA and modification of tRNA 3. profound effects on cell metabolism and viability |
|
Vinka Alkaloids
|
[M-phase][Vinblastine]
1. isolated from vinca rosea FX: bind tubulin and prevent mitotic spindle formation USED: hodgkin's disease, lymphoma, leukemia, kaposi's sarcoma, breast cancer, cervix, lung, ovary, bladder, and testis |
|
Taxoids
|
[M-phase][Paclitaxel/Taxol]
isolated from yew tree bark FX: induce polymerization and stabilization of microtubules USED: metastatic cancer of breast and ovary |
|
Actinomycin D
|
[antibiotic]
FX: intercalates in DNA and inhibits transcription and DNA synthesis USED: Wilm's tumor, ewing tumors, osteosarcoma. Neuroblastoma |
|
Doxorubicin
|
[Adriamycin][anitbiotic]
FX: intercalates in DNA USED: acute leukemia, sarcoma, hodgkin's disease, neuroblastoma, carcinoma of lung, GI tract, endometrium, ovary,thyroid and breast, wilm's tumor, multiple myeloma |
|
Mitomycin
|
[antibiotic]
FX: after intracellular activation, reacts with DNA and inhibits its synthesis USED: carcinoma of head, neck, lung, GI tract, breast, cervix and bladder |
|
Bleomycin
|
[anitbiotic]
FX: chelates metal ions>produces superoxide and hydroxide free radicals>Dna cleavage, lipid peroxidation |
|
Topotecan
|
[isolated from happy tree][nonspecific cell cycle][captothecin]
FX: inhibits topoisomerase I, which leads to single-strand breaks in DNA; inhibits replication and transcription USED: metastatic carcinoma of ovary |
|
Irinotecan
|
[isolated from happy tree][nonspecific cell cycle][captothecin]
FX: inhibits topoisomerase I, which leads to single-strand breaks in DNA; inhibits replication and transcription USED: metastatic cancer of colon and rectum |
|
Etoposide
|
[Epipodophyllotoxins][S-phase]
[isolated from Mayapple plant] FX: inhibit topoisomerase II, which leads to double strand breaks in DNA; causes errors during DNA replication and eventually apoptosis |
|
Teniposide
|
[Epipodophyllotoxins][S-phase]
[isolated from Mayapple plant] FX: inhibit topoisomerase II, which leads to double strand breaks in DNA; causes errors during DNA replication and eventually apoptosis |
|
Cisplatin
|
FX: intra-interstrand crosslinks in DNA
USED: carcinoma of testes, ovary, head, neck, cervix, endometrium, sarcoma, neuroblastoma |
|
As2O3
|
USED: acute promyelocytic leukemia
|
|
Asparaginase
|
FX: depletes Asn levels
USED: acute lymphocytic leukemia |
|
Androgens
|
USED: metastatic breast cancer [may be bad]
|
|
Anti-androgens
|
USED:prostate carcinoma
[Flutamide] |
|
Estrogens
|
USED: high dose used in postmenopausal breast cancer ; prostate cancer [may be bad]
|
|
Anti-Estrogens
|
[Tamoxifen]
USED: postmenopausal breast cancer, metastatic melanoma [maybe] |
|
Letrozole
|
[aromatase inhibitor][estrogen pathway]
FX: prevents the conversion of testosterone to estradiol USED: advanced breast cancer; used in tamoxifen resistance |
|
Fulvestrant
|
[Estrogen pathway downregulator]
FX: leads to the destruction of estrogen receptor USED: given to tamoxifen-resistant patients; generally used after letrozole, though some recommend skipping letrozole. |
|
Tretinoin
|
[retanoic acid receptor][acid form of vit A]
FX: induce the differentiation of undifferentiated cancer cells, targets RAR USED: acute promyelocytic leukemia [APL] Q15d, Q3m SFX:teratogenicity OTHER: acne vulgaris, keratosis pilaris, cosmetics OSFX: sensitivity to sunlight, skin irritation |
|
Alitretinoin
|
[ret acid rec]
FX:target RAR and RXR to induce differentiation of undifferentiated cancer cells USED: treatment of AIDS-related Kaposi's sarcoma Other: severe chronic hand eczema |
|
Bexarotene
|
[retinoic acid receptor]
FX:targets RXR to induce differentiation of undifferentiated cancer cells USED: treatment of cutaneous T cell lymphoma Other: lung cancer, breast cancer, kaposi's sarcoma |
|
What type of treatment is used to stop cancer cells from evading growth suppressors?
|
cyclin-dependent kinase inhibitors
|
|
What typ of treatment is used to stop cancer cells from avoiding immune detection?
|
immune activating anti-CTLA4 mAb
|
|
What type of treatment is used to stop cancer cells from enabling replicative immortality?
|
telomerase inhibitors
|
|
What type of treatment is used to stop cancer cells from having tumor promoting inflammation?
|
selective anti-inflammatory drugs
|
|
What type of treatment is used to stop cancer cells from activating invasion and metastisis?
|
inhibitors of HGF/c Met
|
|
What type of treatment is used to stop cancer cells from inducing angiogenesis?
|
inhibitors of VEGF signaling
|
|
What type of treatment is used to stop cancer cells from creating genome instability and mutation?
|
PARP inhibitors
|
|
What type of treatment is used to stop cancer cells from resisting apoptosis?
|
Proapoptotic BH3 mimetics
|
|
What type of treatment is used to stop cancer cells from deregulating cellular energetics?
|
aerobic glycolysis inhibitors
|
|
What type of treatment is used to stop cancer cells from sustaining proliferative signaling?
|
EGFR inhibitors
|
|
Imatinib
|
[Gleevec]
FX:tyrosine kinase inhibitor [Abl, cKit, PDGFR] USED: chronic myeloid leukemia, acute lymphocytic leukemia, gastrointestinal stromal tumors |
|
Trastuzumab
|
[herceptin][stop proliferative signaling]
FX: humanized monoclonal anti-HER2 antibody used in mutated HER2 patients T.5: 6 d Q7d IV with chemotherapy Q21d IV after surgery/ chemotherapy SFX: cardiac dysfunction |
|
Lapatinib
|
[kinase inhibitor]
FX: HER2 mutation t.5: 24h q1d sfx: nausea, vomiting, heartburn, fatigue |
|
Erlotinib
|
[Tarceva][stop proliferative signaling]
FX:EGFR inhibitor USED: advanced NSCLC; 3 month life extension SFX: rash, diarrhea, fatigue |
|
Gefitinib
|
[Iressa][stop proliferative signaling]
FX: EGFR inhibitor USED: advanced NSCLC SFX: acne, diarrhea, nausea, vomiting |
|
Cetuximab
|
[Erbitux][stop proliferative signaling]
FX: prevents EGF binding USED: squamous cell carcinoma and colon cancer TEST: check for mutation on KRAS |
|
Bevacizumab
|
[Avastin][angiogenesis inhibitor]
FX: prevents VEGF from binding to its receptor USED: metastatic breast cancer OTHER: age-related macular degeneration SFX: risk of bleeding, bowel proliferation |
|
Sunitinib
|
[Sutent][angiogenesis inhibitor]
FX: inhibitor of VEGFRs, PDGFRs, and cKit USED: RCC and imatinib-resistant GIST |
|
Sorafenib
|
[Nexavar][angiogenesis inhibitor]
FX: inhibitor of VEGFR2-3, PDGFR, cKit, Raf-1, B-Raf USED: advanced renal cell carcinoma and unresectable hepatocellular carcinoma |
|
Vemurafenib/zelboraf
|
[Zelboraf][kinase inhibitor]
FX:inhibits V600E B-Raf, not wild type USED: late stage melanoma; 6 months life ext.; regression for 2-18 m |
|
Bortezomib/velcade
|
[Velcade][proteasome inhibitor]
FX: inhibits active site of 26 S proteasome USED: multiple myeloma |
|
What preserves methylation?
|
DNMT1
|
|
What may be unique about a cancer epigenome?
|
1. genome-wide hypomethylation
2. site-specific CpG island promoter hypermethylation |
|
What is one possible bad reason for hypermethylation?
|
the silencing of tumor suppressors
|
|
Azacytidine
|
[Vidaza][DNA demethylating Agent]
FX: inhibits DNA methyltransferase after incorporation into DNA; reactivation of tumor suppressor genes USED: myelodysplastic syndrome |
|
5-Aza-2'-deoxyxytidine
|
[decitabine][DNA demethylating agent]
FX: similar to azacytidine USED: myelodysplastic syndrome |
|
What is HDAC?
|
histone deacetylases
|
|
Vorinostat/ SAHA
|
[Zolinza][HDAC]
FX: reactivates tumor suppressor USED: cutaneous T-cell lymphoma |
|
Romidepsin
|
[Istodax][HDAC]
FX: reactivates tumor suppressor USED: cutaneous t-Cell lymphoma |
|
To improve results when treating epigenetically, what would you use synergistically?
|
1. HDAC
2. demethylating agents |
|
Define immunotherapy.
|
treatment of disease by inducing, enhancing or suppressing an immune response.
|
|
What are the three reasons to use immunotherapy in cancer treatment?
|
1. immune cells kill tumor cells
2. immune cells affect cancer growth and metastisis 3. adjunct treatment to ameliorate SFX of chemotherapy |
|
IL-2
|
[immunotherapy]
FX:antigen binding to T cell receptor leads to secretion of IL-2 T.5:30-90 min Admin: IV USED: metastatic renal carcinoma and malignant melanoma SFX: especially capillary leak [due to activated T cells damaging the endothelium] |
|
IFN-alpha2a
|
[immunotherapy]
FX: induced by viral infection and produced by leukocytes t.5: 2.5 h Admin: SC or IM USED: renal cell carcinoma SFX: myelosuppression and flulike symptoms |
|
IFN-gamma
|
[immunotherapy]
FX: induced by viral infections and produced by T-lymphocytes and NK cells Admin: SC and IV T.5: 30 min USED: renal cell carcinoma SFX: flulike symptoms, GI upset |
|
Levamisole
|
[immunotherapy]
FX: non-specific immunostimulatory properties USED: colon cancer, melanoma, head and neck cancer SFX: suppress the production of leukocytes, inflammatory destruction of blood vessels WITHDRAWN FROM US; common in COCAINE |
|
Briefly describe adoptive immunotherapy for cancer.
|
Take out T cells, select and stimulate IFN-gamma producers, suppress immune system, put selected T cells back
|
|
CAR
|
chimeric antigen receptor [artificial T cell receptor]
|
|
Provenge
|
[sipuleucel-T]
FX: autologous cellular immunotherapy 'cancer vaccine' 3 courses Q 14d ($90000) USED: metastatic, castration-resistant prostate cancer SFX: fever, fatigue, chills, nausea, joint and headache |
|
Ipilimumab
|
[immunotherapy]
FX: blocks CTLA-4 USED: late stage melanoma; possible proatate and lung cancer SFX: potentially fatal immunological adverse effects, GI, Fever |
|
Denileukin Diftitox
|
[Ontak][immunotoxin]
FX:IL-2 conjugated to diptheria toxin USED: cutaneous T cell Lymphoma |
|
Adcetris
|
[immunotoxin]
FX: antibody conjugated to poison USED: refractory Hodgkin's lymphoma and systemis anaplastic large cell lymphoma |
|
On what mutation was the first succesful gene therapy done on?
|
X-linked IL2RG mutation
|
|
ONYX-015
|
oncolytic virus involving p53
|
|
Measles
|
leads to spontaneous regression of leukemias and lymphomas
|
|
What are the common pleiotropic manifestations of neurofibromatosis 1?
|
1. 6 café-au-lait spots over 15mm
2. 1 plexiform neurofibroma or 2 other neurofibromas 3. axillary or inguinal freckling 4. distinstinctive osseous lesion 5. optic glioma 6. 2 lisch nodules 7. affect 1st degree relative 8. mutation in NF1 |
|
How many pleiotropic manifestations are required before you can clinically diagnose neurofibromatosis 1?
|
2
|
|
Genetics of neurofibromatosis
|
Autosomal Dominant; 50 % os cases de novo
|
|
Diagnosis of Neurofibromatosis 2
|
1. bilateral vestibular schwannomas, or
2. a first degree relative with NF2, plus either a. unilateral vestibular schwannoma under age 30y b. Two of the following: neurofibroma, meningioma, gliomma, schwannoma, juvenile posterior subscapsular lenticular opacity 'cataract' 3. unilateral vestibular schwannoma and any two: neurofibroma, meingioma, glioma, schwannoma, cataract 4. multiple meningiomas and a. inilateral vestibular schwannoma b. any two of: neurofibroma, glioma, schwannoma, cataract |
|
Legius Syndrome
|
SPRED1
café au lait spots axillary freckling nodules are lipomas, not neurofibromas mild disorder |
|
What did Osler believe?
|
The body is a machine and there is one root cause proximate; look for similarity between cases
|
|
What did Garrod believe?
|
Disease is caused by incongruence between the body and environment, disease can come from many causes, near or far, and every case is different.
|